Aims: We asked whether the neuroprotective effect of cholinergic microglial stimulation during an ischemic event acts via a mechanism involving the activation of nuclear factor erythroid-2-related factor 2 (Nrf2) and/or the expression of its target cytoprotective gene, heme oxygenase-1 (HO-1). Specifically, the protective effect of the pharmacologic alpha-7 nicotinic acetylcholine receptor (a7 nAChR) agonist PNU282987 was analyzed in organotypic hippocampal cultures (OHCs) subjected to oxygen and glucose deprivation (OGD) in vitro as well as in photothrombotic stroke in vivo. Results: OHCs exposed to OGD followed by reoxygenation elicited cell death, measured by propidium iodide and 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide staining. Activation of a7 nAChR by PNU282987, after OGD, reduced cell death, reactive oxygen species production, and tumor necrosis factor release. This was associated with induction of HO-1 expression, an effect reversed by abungarotoxin and by tin-protoporphyrin IX. The protective effect of PNU282987 was lost in microglial-depleted OHCs as well as in OHCs from Nrf2-deficient-versus-wild-type mice, an effect associated with suppression of HO-1 expression in microglia. Administration of PNU282987 1 h after induction of photothrombotic stroke in vivo reduced the infarct size and improved motor skills in Hmox1 lox/lox mice that express normal levels of HO-1, but not in LysM
Introduction

I
schemic damage results from a cascade of cellular and molecular events triggered by a sudden lack of blood flow and subsequent reperfusion of the ischemic territory. Postischemic inflammation is characterized by an orderly sequence of events involving a rapid activation of microglial cells, followed by infiltration of various circulating leukocytes, including granulocytes (neutrophils), T-cells, and monocytes/macrophages that irrupt in the ischemic parenchyma because of the blood-brain barrier (BBB) breakdown
Innovation
We demonstrate the role of microglial alpha-7 nicotinic acetylcholine receptor (a7 nAChR) in providing neuroprotective and anti-inflammatory actions under brain ischemia conditions by a mechanism that implicates the induction of heme oxygenase-1 expression via nuclear factor erythroid-2-related factor 2 activation. Our data support the notion that microglial a7 nAChR might be targeted therapeutically to modulate the brain cholinergic anti-inflammatory pathway. (23, 30) . The specific role of microglia in this pathological scenario remains controversial. Microglial activation has been linked to the upregulation of the proinflammatory cytokines such interleukin (IL)-1b and tumor necrosis factor (TNF), chemokines, and reactive oxygen species (ROS), which contribute to tissue damage progression (18, 37) . There is also an increasing body of evidence demonstrating the protective role of microglia in stroke. Postischemic production of TGF-b and IL-10 by microglia may facilitate tissue repair by exerting direct cytoprotective effects on surviving cells in the ischemic penumbra and promoting the resolution of inflammation (9, 34) . This notion is strongly supported by a recent study showing the beneficial effects of human microglia transplanted into rats subjected to the experimental focal brain ischemia (40) .
Nicotinic acetylcholine receptors (nAChRs) are a family of ligand-gated ion channels and are members of the Cys-loop receptor superfamily (35) . Activation of the a7 nAChR is protective against a wide variety of cytotoxic stimuli, such as glutamate (53) , oxygen and glucose deprivation (OGD) (15) , and kainic acid (50) . In recent years, nAChRs were shown to regulate inflammation, in particular via the a7 nAChR activation in macrophages (61) , which regulates the cholinergic antiinflammatory pathway (26, 28, 48, 61) . The transcripts for the nAChR subunits a7, a3, a5, as well as b4 have been detected in multiple inflammatory cell types, including macrophages and microglia, the resident macrophages of the brain (16, 47) .
The transcription factor Nrf2 (nuclear factor erythroid-2-related factor 2) is a master regulator of redox homeostasis (22) . Nrf2 controls the expression of phase II enzymes that act in a cytoprotective manner against oxidative stress, including heme oxygenase-1 (HO-1) (2) and the catalytic subunit of glutamate cysteine ligase (GCL-c). HO-1 serves a vital metabolic function as the rate-limiting step in the oxidative catabolism of heme to generate carbon monoxide (CO), biliverdin, and ferrous iron (56) ; biliverdin is subsequently converted to bilirubin by biliverdin reductase. These three byproducts, and in particular CO, have been related to cytoprotection (5) during ischemic injury, (1) including cerebral ischemia (27, 60, 65) . Moreover, CO regulates monocyte/ macrophage activation (42) , an effect associated with protection against different experimental models of disease (43, 51) . Induction of HO-1 expression by different nicotinic receptor agonists and its importance in the maintenance of antiinflammatory effects have been recently reported (57) . On the other hand, induction of GCL-c, the rate-limiting enzyme of the novo synthesis of glutathione (GSH), by melatonin increases the levels of GSH and protects against oxidative stress (58) .
Although the participation of a7 nAChR in the cholinergic anti-inflammatory pathway is well documented in the periphery (61), there is little evidence related to its participation in the central nervous system. In this context, we used a highly selective microglial-target toxin and the selective a7 nAChR agonist PNU282987 to evaluate the neuroprotective and antineuroinflammatory effects of the microglial a7 nAChRs. Further, we used Nrf2-deficient (Nrf2 -/ -) mice and LysM
Cre
Hmox1
D/D mice to assess the participation of this transcription factor in the regulation of HO-1 in the microglial cells and in the neuroprotective effect mediated by a7 nAChR activation. We found that microglial-a7 nAChR activation is crucial in the neuroprotective effect afforded by PNU282987, an effect mediated via a mechanism involving Nrf2 activation and HO-1 expression.
Results
Cell death induced by OGD in OHCs
We first established the experimental conditions required to test the protective role of the a7 nAChR agonist PNU282987. To determine the optimum period of OGD and reoxygenation (Reox), organotypic hippocampal cultures (OHCs) were subjected to 15 or 30 min of OGD followed by a 24-or 48-h Reox period. Cell death was measured in the CA1 subfield, which is considered to be the most vulnerable to hypoxia/anoxia (63) . OGD for 15 or 30 min increased cell death by 177%-161% and 234%-243%, as compared to normoxia, respectively. No significant differences were found between 24-and 48-h Reox, independently of the OGD periods applied (Fig. 1) . We therefore selected 15-min OGD followed by 24-h Reox as the standard protocol to perform the following studies.
Effect of post-OGD administration of the a7 nAChR agonist PNU282987 on OHC viability
To evaluate the protective properties of a7 nAChR, OHCs were treated with the a7 nAChR agonist PNU282987 at different concentrations (1, 3, and 10 lM) during the 24-h Reox period (see protocol in Fig. 2A ). OGD (15 min) followed by Reox (24 h) increased cell death as assessed by propidium iodide (PI) fluorescence in CA1 (compare the basal condition in Fig. 2B with Fig. 2C ). Post-OGD treatment with increasing concentrations of PNU282987 reduced PI staining (Fig. 2D-F) . PNU282987 significantly reduced cell death measured as PI uptake at the concentrations of 10 lM (110% -10%) and 30 lM (142% -12%) in comparison to OHCs subjected to OGD alone (180% -2%) (Fig. 2G) .
FIG. 1.
Oxygen and glucose deprivation (OGD) increases cell death in organotypic hippocampal slices. Cell death was labeled with propidium iodide (PI) fluorescence corrected for the number of nuclei (Hoechst) in the CA1 subfield of rat organotypic slices after 15 or 30 min of OGD followed by 24 or 48 h of reoxygenation (Reox). Data are mean -SEM of seven independent experiments, ***p < 0.001, **p < 0.01 with respect to the basal.
The cell viability was also assessed by the colorimetric determination of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. Considering the cell viability in basal OHCs as 100%, OGD reduced the cell viability by 40%; under these experimental conditions, maximum protection offered by PNU282987 was also achieved at 10 lM (60%; Fig. 2H ). We therefore selected the concentration of 10 lM to evaluate the protective mechanism of action of a7 nAChR stimulation against OGD-induced toxicity in OHCs.
Participation of the a7 nAChR/Nrf-2/HO-1 axis in the neuroprotective effect of PNU282987
Although it is accepted that PNU282987 is a selective a7 nAChR agonist (19) , we wanted to prove that the neuroprotective effect of PNU 282987 is mediated by this receptor. We used the protocol illustrated in Figure 2A in the absence or presence of a-bungarotoxin (BGT; 100 nM), a selective a7 nAChR antagonist. Inhibition of cell death associated with OGD/Reox by PNU282987 was abrogated by BGT (Fig. 3A) , suggesting that this protective effect is indeed mediated via a7 nAChR activation.
In other models of oxidative stress injury, the neuroprotective effect of PNU282987 has been suggested to be mediated via a mechanism involving HO-1 (44) . We tested the involvement of this heme-catabolizing enzyme under our experimental conditions. The protective effect of PNU282987 (10 lM) was associated with a 2.2-fold increase in HO-1 expression, as detected by Western blotting and as compared with untreated controls (Fig. 3B ). This effect was reversed by BGT, suggesting that a7 nAChR activation induces the expression of HO-1. Inhibition of cell death by PNU282987 was also abrogated by tin (Sn)-protoporphyrin-IX (SnPP; 3 lM), an inhibitor of HO activity (Fig. 3A) , corroborating the Values are expressed as mean -SEM of at least five independent experiments; ***p < 0.001, **p < 0.01 compared to the basal. ### p < 0.001, # p < 0.05 with respect to OGD-treated slices in the absence of PNU282987. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars participation of HO-1 in the protective effect of PNU282987. We evaluated the induction of GCL-c, another phase II enzyme. As shown in Figure 3C , PNU282987 (10 lM) increased GCL-c expression by 1.6-fold, as compared with controls. This effect was inhibited by BGT and by SnPP, suggesting that a7 nAChR activation induces the expression of phase II enzymes, presumably conferring neuroprotection against OGD.
Given that HO-1 expression is tightly regulated by Nrf2 (2), we setup to determine the participation of this transcription factor in the protective effect of PNU282987. The neuroprotective effect of PNU282987 against OGD was lost in OHCs from Nrf2 -/ -versus Nrf2 + / + mice (Fig. 4A ). This was associated with the concomitant loss of HO-1 induction in OHC from Nrf2
-/ -versus Nrf2 + / + mice, treated in both cases with 
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PNU282987 (Fig. 4B
). This suggests that the protective effect of PNU282987 acts via a mechanism that involves the induction of HO-1 by Nrf2.
Antioxidant and anti-inflammatory effect of PNU282987
There is accumulating evidence implicating ROS and inflammation as pivotal mediators of acute responses of the brain to ischemia and its chronic pathogenic progression (25, 31) . OGD (15 min) followed by Reox (24 h) doubled the amount of ROS (measured by H 2 DCFDA) produced in OHCs, as compared to the control (Fig. 5A ). PNU282987 (10 lM) reduced ROS production significantly, as compared to the untreated controls. This effect was blocked by SnPP and by BGT as well, suggesting that the antioxidant effect triggered upon a7 nAChR activation is mediated by a mechanism involving HO-1.
To test the effects of PNU282987 on the production of cytokines induced by OGD/Reox, TNF and IL-10 were quantified by an enzyme-linked immunosorbent assay (ELISA) in the culture medium of OHCs. OGD (15 min) followed by Reox (24 h) increased TNF secretion, as compared to the control OHCs (477 -50 pg/ml vs. 109 -22 pg/ml). Treatment of OHCs with PNU 282987 10 lM reduced TNF release almost to the control levels (163 -22 pg/ml). This inhibitory effect was prevented by SnPP (3 lM) as well as by BGT (100 nM) (429 -59 pg/ml; 377 -82 pg/ml, respectively). We did not observe changes in IL10 secretion in any of the conditions tested (data not shown). These results suggest that a7 nAChR activation inhibits the production of proinflammatory cytokines, TNF, via a mechanism involving the expression of HO-1. compared to the nondepleted OHCs (Fig. 6C) . Induction of HO-1 expression by PNU282987 was also reduced in microglia-depleted OHCs, as compared to the control OHCs (Fig.  6D ). This shows that a7 nAChR activation in microglia induces the expression of HO-1 in microglia.
PNU282987 reduces the cortical infarct volume through the induction of HO-1 expression
We used the photothrombotic model of stroke in mice to evaluate whether the protective effects of PNU282987 act under brain ischemic conditions in vivo (10) . Following the protocol shown in Figure 7A , ischemia induced by photothrombosis caused a mean cortical infarct volume of 15.7% -0.9%. Administration of PNU282987 (10 mg/kg), 1 h postphotothrombosis, reduced the infarct volume by 40% (9.4% -0.4%). Administration of Zinc (III)-deuteroporphyrin IX-2,4 bisethylene glycol (ZnDPBG; 10 mg/kg), a potent HO inhibitor that crosses the BBB (24), did not alter the infarct volume, but prevented the neuroprotective effect of the a7 nAChR agonist PNU282987 to 14.6% -0.8% (Fig. 7B) .
To establish conclusively the involvement of HO-1, we compared the protective effect of PNU282987 against ischemia induced by photothrombosis in Hmox1 lox/lox mice expressing normal levels of HO-1 versus LysM
Cre Hmox1 D/D in which HO-1 expression is inhibited specifically in myeloid cells (see the Methods section and Supplementary Fig. S2 ), including in the microglia. PNU282987 reduced the infarct volume by 38% in Hmox1 lox/lox mice, as compared to untreated Hmox1 lox/lox mice. Reduction in the infarct volume correlated with improved motor coordination measured by hindpaw slips in the beam-walking test (BWT) (Fig. 7E) . In contrast, PNU282987 failed to reduce the infarct volume or to improve motor coordination in LysM Cre Hmox1 D/D mice ( Fig. 7C-E ). This reveals that the expression of HO-1 in the myeloid compartment, and presumably in the microglia, is essential to support the neuroprotective effect of a7 nAChR against brain ischemia induced by photothrombosis.
Discussion
In the present study, we provide experimental evidence in vitro as well as in vivo, pointing to the crucial role of microglia in the neuroprotective effect afforded by the selective a7 nAChR agonist PNU282987 against brain ischemia. Although there is convincing evidence that a7 nAChR activation in macrophages exerts anti-inflammatory effects mediating the so-called cholinergic anti-inflammatory pathway (61), few . To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars studies have addressed specifically whether this effect is also exerted in microglia, the resident macrophages of the brain. We provide evidence that a7 nAChR activation induces the expression of HO-1 in microglia, which is required to support the neuroprotective effect of PNU282987 against brain ischemia. This notion is supported by the following independent observations: (i) PNU282987 induces HO-1 expression at the concentration that afforded maximum protection against brain ischemia; (ii) the protective effect of PNU282987 is lost by inhibition of the HO activity (Figs. 2 and 3) ; (iii) induction of HO-1 by PNU282987 is ablated by deletion of the transcription factor Nrf2 (Fig. 4) ; (iv) the protective effect of PNU282987 is reversed by microglia deletion, an effect associated with the loss of HO-1 expression (Fig. 6) ; and (v) the protective effect of PNU282987 is ablated by specific deletion of HO-1 in myeloid cells, including the microglia (Fig. 7) .
Signaling through nAChRs plays an important role in various processes such as neurite outgrowth, control and synthesis of neurotrophic factors, neuroprotection (20) , as well as in the regulation of inflammation (48, 61) . Moreover, signaling via a7 nAChR protects against neuronal death in different models of hemorrhagic brain injury (13, 29) . We have also previously shown that a7 nAChR activation is protective in different in vitro models of ischemia/Reox (15, 44) . Most of these studies have focused their attention on neuronal nicotinic receptors, while the participation of nAChRs in other brain cells such as astrocytes and microglia has been less studied. The results obtained in the present work indicate that a7 nAChRs expressed in microglia are key elements in promoting the protective effect of PNU282987. This notion is supported by the observation that the selective a7 nAChR antagonist a-BGT prevented the neuroprotective effect and the induction of phase II enzymes (HO-1 and GCL-c) by PNU282987, and hence the reduction of ROS production and TNF release (Fig. 5) . Moreover, the protective effect of PNU282987 against brain ischemia is reduced by 70% upon microglial deletion (Fig. 6 ). These observations strongly suggest that the cholinergic anti-inflammatory pathway described for peripheral macrophages, as controlling systemic inflammation, may have a brain counterpart, where microglias, the resident macrophages of the brain, regulate inflammation via activation of the a7 nAChRs.
Recent findings have elucidated the cellular signaling pathways and molecular mechanisms that mediate adaptive stress response that typically involves the synthesis of various stress resistance proteins as the products of vitagenes, a group of genes strictly involved in preserving cellular homeostasis during stressful conditions (6) . The vitagene family is composed of the heat shock proteins (Hsp) HO-1/Hsp32, Hsp70, and Hsp60, by the thioredoxin system and by sirtuin proteins. Nrf-2 is a master regulator of cellular redox homeostasis, controlling the expression of different genes that modulate the cellular redox status and inflammation (phase II enzymes), including HO-1 (22) . Induction of HO-1 expression has generally been considered to provide an adaptive cytoprotective response against the toxicity of oxidative stress (17, 45, 59 ). Hmox1-deficient mice develop chronic inflammatory lesions that are similar to the ones observed in individuals lacking the HO-1 expression (64). Hence, compounds targeting the vitagene network could be a novel approach to delay various alterations in cells, tissues, and organs and potentially prevent and treat many different diseases, such as ischemia. The mechanisms regulating the salutary effects of HO-1 remain however to be fully established (52) .
The protective effect of PNU282987 acts via activation of Nrf2, as demonstrated by the loss of this protective effect in OHCs from Nrf2 -/ -mice (Fig. 4A ). This effect is associated with inhibition of HO-1 expression in microglial cells from OHCs Nrf2
-/ -versus Nrf2 + / + (Fig. 4B and Supplementary  Fig. S2 ). Recently, it has been hypothesized that pharmacological modulation of Nrf2 restores the cellular redox state through the expression of antioxidant phase II enzymes, downmodulating the pathological neuroinflammatory response of reactive microglia (21) . Heme degradation by HO-1 in microglia generates CO (33), a gasotransmitter that can inhibit NADPH oxidase (55), the main enzyme responsible for microglial ROS production (4) promoting microglial activation during neuroinflammation (7). PNU282987 reduces ROS production as well as TNF release induced by brain ischemia, an effect mediated by the induction of HO-1 expression via a7 nAChR signaling (Fig. 5A, B) . This corroborates the importance of the Nrf-2/HO-1 system in the control of the cellular redox state and modulation of the neuroinflammatory responses to ischemia. We infer that nAChR signaling modulates microglial activation via a mechanism mediated by Nrf2/HO-1, which inhibits ROS production.
Microglias have historically been viewed as immunocompetent cells that respond to inflammation by acting as antigenpresenting cells or secreting cytokines. The specific role of microglia in postischemic inflammation remains controversial. Resident microglia are activated rapidly in response to brain injury, within minutes of ischemia onset, and produce proinflammatory mediators, such TNF and IL-1b, which exacerbate brain damage (18, 37) . Our data show that cell death induced by OGD was significantly higher in microgliadepleted OHCs compared to nondepleted slices (Fig. 6) . Hence, in our model, microglial cells have a protective role in the brain against ischemic injury.
We found that expression of HO-1, presumably in the microglia, mediates the protective effect of PNU282987 against photothrombotic brain ischemia, as assessed in Hmox1 lox/lox mice, expressing the normal levels of HO-1 versus LysM Cre Hmox1 D/D , in which HO-1 expression is inhibited specifically in myeloid cells, including in the microglia. Together with the data obtained in the OHC model, this suggests that expression of HO-1 by microglia is important to resolve the oxidative stress and neuroinflammation and, most importantly, to stop the progression of cell death induced by an ischemic episode. This is in line with the notion that microglia plays a central role in the regulation of brain ischemia and excitotoxic injury (32, 40, 41) . We propose that pharmacologic modulation of HO-1 in microglia may be considered as a potential strategy against a brain ischemia-induced injury (62) .
Materials and Methods
Animals and preparation of OHC
OHCs were conducted on 8-10-day-old Sprague-Dawley rats or wild-type C57BL/6 mice and Nrf2-knockout mice of the same littermates. Nrf2-knockout mice were kindly provided by Dr. Antonio Cuadrado (Department of Biochemistry, School of Medicine, Universidad Autó noma de Madrid). All animal assays were carried out following the European ; 100 U/ml penicillin and 0.100 mg/ml gentamicin. Approximately 4-6 slices were placed on Millicell 0.4-lm culture insert (Millipore) within each well of a six-well culture tray with the medium, where they remained for 7 days. The culture medium, which consisted of 50% minimal essential medium, 25% HBSS, and 25% heat-inactivated horse serum, were purchased from Life Technologies. The medium was supplemented with 3.7 mg/ml d-glucose, 2 mmol/l lglutamine, and 2% of B-27 Supplement Minus antioxidants (Life Technologies), and 100 U/ml penicillin. OHCs were cultivated in a humidified atmosphere at 37°C and 5% CO 2 , and the medium was changed twice a week.
Mice
C57BL/6 Nrf2
-/- (22) and Hmox1 LoxP (38) mice were generated by the laboratory of Dr. Masayuki Yamamoto (Tohoku University Graduate School of Medicine) and obtained through the RIKEN BioResource Center (Nrf2 Cre allele. Mice were genotyped by the polymerase chain reaction (PCR) from genomic DNA using the following primers for the Hmox1 allele (Hmox1 wild-type forward 5¢-CTCACTATGCAACTCTGTTGGAGG-3¢, Hmox1 wild-type reverse 5¢-GTCTGTAATCCTAGCACTCGAA-3¢ and Hmox1
LoxP reverse 5¢-GGAAGGACAGCTTCTTGTA GTCG-3¢) and for the LysM Cre allele (mutant 5¢-CCCAGA AATGCCAGATTACG-3¢; common: 5¢-CTTGGGCTGCCAG AATTTCTC-3¢ and wild type 5¢-TTACAGTCGGCCAG GCTGAC-3¢). Mice were bred at the Instituto Gulbenkian de Ciência with food and water provided ad libitum. Mice were used at 6 to 12 weeks of age, and the littermates were used as controls.
Thioglycollate-induced peritoneal macrophages
Briefly, mice received (intraperitoneal [i.p], 2 ml) a 3% thioglycollate solution (w/v), and macrophages were obtained by peritoneal lavage 5 days, thereafter in phosphatebuffered saline (PBS; 5 ml).
Peritoneal macrophages were stained with an Alexa467-conjugated-anti-CD11b (M1/70; 1:50 dilution) mAb, and nonspecific Fc binding was inhibited using an anti-FcgIII/II receptor antibody (2.4G2; 1:50 dilution) in PBS 2% fetal calf serum (FCS) (20 min, 4°C) . After washing and centrifugation (PBS 2% FCS; 666g, 2 min, 4°C), cells were sorted as CD11b . Cells were collected and analyzed by flow cytometry (FACSAria; BD Biosciences), using BD FACSDiva Software (BD Biosciences) for acquisition. Postacquisition analysis was performed with FloJo software (Treestar).
RNA isolation and qRT-PCR
Briefly, mRNA was isolated from CD11b
+ -sorted cells and extracted with the RNeasy Mini Kit (Qiagen). cDNA was synthesized from 0.3-0.5 lg of RNA using random hexamer primers (0.3 mg/reaction; Invitrogen) and dNTPs (0.5 mM/ reaction; Invitrogen) (5 min, 65°C). 5 · First Strand buffer (Invitrogen) was added in the presence of dithiothreitol (10 mM/reaction; Invitrogen) and RNAse Out recombinant ribonuclease inhibitor (40 U/reaction; Invitrogen) (2 min, 42°C). SuperScriptII reverse transcriptase (200 U/reaction; Invitrogen) was added completing a final volume of 20 ll (50 min, 42°C; 15 min, 70°C). One ll of cDNA was used for PCRs (10 ll) using the Power SYBRGreen PCR master mix (Applied Biosystems) and optimal primer concentrations (previously determined for each transcript). PCR products were detected by quantitative real time-PCR (ABI-7900HT; Applied Biosystems) (2 min, 50°C, 10 min, 95°C, and 40 cycles of 15 s at 95°C, 1 min, 60°C). Primers used to amplify mouse mRNA transcripts were designed using the Primer3 software (Whitehead Institute for Biomedical Research, Steve Rozen and Helen Skaletsky) according to the specifications of the ABI-7900HT equipment (Applied Biosystems) and are listed below: Hmox1 5¢-AAGGAGGTACACATCCAAGCCGAG-3¢ and 5¢-GATATGGTACAAGGAAGCCATCACCAG-3¢; Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 5¢-AAC TTTGGCATTGTGGAAGG-3¢ and 5¢-ACACATTGGGGG TAGGAACA-3¢. The transcript number was calculated from the Ct of each gene using a 2
-DDCT method (relative number) and normalizing results to GAPDH.
Oxygen-glucose deprivation in OHCs
Oxygen-glucose deprivation was used as an in vitro model of cerebral ischemia. The inserts with slice cultures were placed in 1 ml of OGD solution composed of the following (in mM): NaCl 137.93, KCl 5.36, CaCl 2 2, MgSO 4 1.19, NaHCO 3 26, KH 2 PO 4 1.18, and 2-deoxyglucose 11 (Sigma-Aldrich). The cultures were then placed in an airtight chamber (Billups and Rothenberg), and were exposed to 5 min of 95% N 2 /5% CO 2 gas flow to ensure oxygen deprivation. After that, the chamber was sealed for 15 min at 37°C. The control cultures were maintained for the same time under a normoxic atmosphere in a solution with the same composition as that described above (OGD solution), but containing glucose (15 mM) instead of 2-deoxyglucose. After the OGD period, the slice cultures were returned to their original culture conditions for 24 h (reoxygenation period).
Quantification of cell death in OHCs
Quantification of viability by MTT. The cell viability, virtually the mitochondrial activity of living cells, was measured using the quantitative colorimetric assay of MTT, as described previously (11) with some modifications. Briefly, 1 ml of the MTT-labeling reagent, at a final concentration of 0.5 mg/ml, was added to the medium of each well at the end of the OGDReox period or normoxic period, and the plate was placed in a humidified incubator at 37°C with 5% CO 2 and 95% air (v/v) for an additional 30 min. Then, the insoluble formazan was dissolved with dimethyl sulfoxide; the colorimetric determination of MTT reduction was measured at 540 nm. Control cells treated under normoxic conditions with vehicle were taken as 100% viability.
Propidium iodide uptake. Cell death was determined in the CA1 region by staining the OHCs with PI. Thirty minutes before analyzing fluorescence, slices were incubated with PI (1 lg/ml) and Hoechst (5 lg/ml); Hoechst staining was used to normalize PI fluorescence with respect to the number of nuclei. Fluorescence was measured in a fluorescence-inverted NIKON Eclipse T2000-U microscope. The wavelengths of excitation and emission for PI and Hoechst were 530 or 350, and 580 or 460 nm, respectively. Images were taken at CA1 at magnifications of 10 · . The Metamorph programme version 7.0. was used for fluorescence analysis. To calculate cell death, we divided the mean PI fluorescence by the mean Hoechst fluorescence, as previously described (14) . Data were normalized with respect to the control values that were considered as 1.
ROS measurement in OHCs
To measure the cellular ROS, we used the molecular probe H 2 DCFDA as previously described (44) . Briefly, organotypic hippocampal slices were loaded with 10 lM H 2 DCFDA, which diffuses through the cell membrane and is hydrolyzed by intracellular esterases to the nonfluorescent form dichlorofluorescein (DCFH). DCFH reacts with intracellular H 2 O 2 to form dichlorofluorescin, a green fluorescent dye. Fluorescence was measured in a fluorescence-inverted NI-KON Eclipse T2000-U microscope. Wavelengths of excitation and emission were 485 and 520 nm, respectively.
Determination of cytokine levels in the culture medium of OHCs TNF and IL-10 levels were measured by using specific ELISA kits. Supernatant samples were obtained at the indicated times and subjected to the ELISA analysis according to the recommendations of the supplier (R&D SystemsBioNova).
Immunotoxic depletion of microglial cells in OHCs
Hippocampal slices were cultured for 5 days and then exposed to 3 or 5 nM of the immunocomplex Mac1-sap (Advanced Targeting Systems) for 7 days. At the end of this period, the slices were fixed with paraformaldehyde 4% for immunohistochemistry. The OGD experiments in microgliadepleted OHCs were performed at the end of the immunotoxic treatments.
Histochemistry for microglia
The OHCs were fixed with 4% paraformaldehyde in 0.1 M phosphate buffer (PB, pH 7.4) and were subsequently cryoprotected for 2 days in 30% sucrose in 0.1 M PB. The endogenous peroxidase was inactivated with 1% H 2 O 2 , and the OHCs were then incubated in a blocking solution (PBS, 10% bovine serum albumin, and 10% normal goat serum) for 1 h, and rabbit anti-IBA1 was used as the primary antibody 1:1000 (Wako Chemicals, Rafer S.L) overnight. The secondary antibody was biotinylated goat anti-rabbit (Vector Labs; 1:200; 2 h) and was dissolved in a blocking solution. The OHCs were incubated in an avidin-biotin peroxidase complex (Kit ABC EliteÒ, 1:250 in PBS; Vector Laboratories) for 2 h and reacted with diaminobenzidine (0.05%; Sigma) with H 2 O 2 (0.003% of the stock 30% solution). The intensity of the staining was checked every few minutes under a microscope, and when labeling was satisfactory, the reaction was stopped by rinsing the OHCs with a cold PB. After several washes with PB, the OHCs were dehydrated in ethanol, defatted with xylene, and coverslipped with DePeX. Negative controls for the specificity of the secondary antibody were prepared by omitting the primary antibody.
Immunoblotting and image analysis
After treatments, the slices were carefully separated from the inserts and lysed in 100 ll ice-cold lysis buffer (1% Nonidet P-40, 10% glycerol, 137 mM NaCl, 20 mM Tris-HCl, pH 7.5, 1 lg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride, 20 mM NaF, 1 mM sodium pyrophosphate, and 1 mM Na 3 VO 4 ). Protein (30 lg) from this cell lysate was resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to the Immobilon-P membranes (Millipore Corp.). The membranes were incubated with anti-HO-1 (1:1000; Chemicon), anti-GCLc subunit (1:10000; a generous gift from Dr Cuadrado A), or anti-b-actin (1:100,000; Sigma). Appropriate peroxidase-conjugated secondary antibodies (1:10,000) were used to detect the proteins by enhanced chemiluminescence. Different band intensities corresponding to immunoblot detection of protein samples were quantified using the Scion Image program. Immunoblots correspond to a representative experiment that was repeated 4-5 times with similar results.
Microglial cell culture
Microglias were isolated using a mild trypsinization method as previously described (49) with brief modifications. Mixed glial cultures were prepared from the cerebral cortices of 3-day-old Sprague-Dawley rats. After mechanical dissociation, cells were seeded in Dulbecco's modified Eagle's medium (DMEM)/F12 with 20% of fetal bovine serum (FBS) at a density of 300,000 cells/ml and cultured at 37°C in humidified 5% CO 2 /95% air. The medium was replaced after 5 days in vitro (DIV) for DMEM/F12 with 10% FBS. The confluency was achieved after 10-12 DIV. High enriched microglial cultures were obtained with a trypsin solution (0.25% trypsin and 1 mM EDTA) diluted 1:4 in DMEM-F12. This process resulted in the detachment of an upper layer of cells in one piece, and microglial cells were attached to the bottom of the well. A great majority of cells (99%) were positive for CD11b, as judged by the immunocytochemical criteria.
Photothombotic stroke model
All animal assays were carried out following the European Community Council Directive issued for these purposes and were approved by the Ethics Committee of the Facultad de Medicina, Universidad Autó noma de Madrid. Every effort was made to minimize the number of animals used and their suffering. Mice were housed individually under controlled temperature and lighting conditions with food and water provided ad libitum. To induce ischemia, animals were anesthetized with 1.5% isoflurane in oxygen under spontaneous respiration. Mice were then placed in a stereotaxic frame (David Kopf Instruments), and the body temperature was maintained at 37°C -0.5°C using a servo-controlled rectal probe-heating pad (Cibertec). A midline scalp incision was made, and the skull was exposed with removal of the periosteum, and both the bregma and lambda points were identified. A cold light (Zeiss KL 1500 LCD) was centered using a micromanipulator at 0.2 mm posterior and 1.5 mm lateral to bregma on the right side using a fiber optic bundle of 2 mm in diameter. According to the Paxinos mouse brain atlas, the primary motor cortex, secondary motor cortex, and primary somatosensory cortex (hindlimb and forelimb) are lying beneath this stereotaxic position. One milligram (0.1 ml) of the photosensitive dye Rose Bengal (Sigma-Aldrich) dissolved in sterile saline was injected i.p., and 5 min later, the brains were illuminated through the intact skull for 20 min. After completion of the surgical procedures, the incision was sutured, and the mice were allowed to recover.
Drug administration protocol
Mice were randomly divided into four groups: subjected to ischemia and treated with 0.9% NaCl sterile saline (ischemia control group), treated with 10 mg/kg PNU282987 dissolved in saline containing 5% DMSO, treated with ZnDPBG dissolved in DMSO, and diluted in physiological saline at a dose of 10 mg/kg (12), or with the combination of PNU282987 and ZnDPBG at the concentrations mentioned above. PNU282987 and ZnDPBG treatments were given i.p after ischemia (1 h and 15 min, respectively).
Measurement of infarct volume
Animals were sacrificed by decapitation 24 h after the ischemic insult. The brains were quickly removed and coronally sectioned into 1-mm-thick slices. For delineation of the infarct area, the brain slices were incubated in a 2% solution of triphenyltetrazolium chloride and then fixed in a buffered formalin solution, and the unstained area was defined as infarcted tissue. Morphometric determination of the cortical infarct volume was obtained using an unbiased stereological estimator of volume based on Cavalieri's principle (3).
Beam-walk test
Motor coordination of mice was assessed 24 h after the photothrombotic stroke by measuring the number of contralateral hindpaw slips in the Beam-walk apparatus (36, 46) . This test takes place over three consecutive days: 2 days of training and 1 day of testing. In the BWT, mice have to go through a 520-mm beam with a flat surface of 10-mm width resting 50 cm above the tabletop on two poles. A black goal box (150 mm · 150 mm · 150 mm) is placed at the end of the beam as the finish point. The amounts of hindpaw slips that occur in the process were counted.
Statistics
Data are given as mean -SEM. Differences between the groups were determined by applying a one-way ANOVA followed by a Newman-Keuls post-hoc or two-way ANOVA, followed by a Bonferroni post hoc test when appropriate.
